Contact
searchSearch
HMP Global
Login

Chronic Lymphocytic Leukemia Excellence Forum

Chronic Lymphocytic Leukemia
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Javier Pinilla Ibarz, MD, PhD
Videos
Evolving Role of CAR-T and Bispecific Therapies in Chronic Lymphocytic Leukemia
04/21/2026
Javier Pinilla-Ibarz, MD, PhD
Javier Pinilla Ibarz, MD, PhD, discusses the evolving role of CAR T-cell therapy and bispecific antibodies in chronic lymphocytic leukemia.
Javier Pinilla Ibarz, MD, PhD, discusses the evolving role of CAR T-cell therapy and bispecific antibodies in chronic lymphocytic leukemia.
Javier Pinilla Ibarz, MD, PhD,...
04/21/2026
Oncology
Justin Taylor, MD
Videos
Next-Generation BTK Degraders for Patients With Chronic Lymphocytic Leukemia
04/21/2026
Justin Taylor, MD
Justin Taylor, MD, discusses the emerging role of Bruton's tyrosine kinase degrader therapies in chronic lymphocytic leukemia.
Justin Taylor, MD, discusses the emerging role of Bruton's tyrosine kinase degrader therapies in chronic lymphocytic leukemia.
Justin Taylor, MD, discusses the...
04/21/2026
Oncology
Jennifer Brown, MD, PhD
Videos
Bruton's Tyrosine Kinase Inhibitor Resistance and Treatment Sequencing in Chronic Lymphocytic Leukemia
04/13/2026
Jennifer Brown, MD, PhD
Jennifer Brown, MD, PhD, discusses mechanisms of resistance to BTKi in chronic lymphocytic leukemia, including mutations associated with both covalent and non-covalent agents.
Jennifer Brown, MD, PhD, discusses mechanisms of resistance to BTKi in chronic lymphocytic leukemia, including mutations associated with both covalent and non-covalent agents.
Jennifer Brown, MD, PhD,...
04/13/2026
Oncology
Erin Mulvey, MD
Videos
Advances in Targeted and Immunotherapy for Richter Transformation
04/10/2026
Erin Mulvey, MD
At the 2026 LL&M Winter Symposium, Erin Mulvey, MD, discusses the evolving treatment landscape for Richter transformation.
At the 2026 LL&M Winter Symposium, Erin Mulvey, MD, discusses the evolving treatment landscape for Richter transformation.
At the 2026 LL&M Winter...
04/10/2026
Oncology
Richard Furman, MD
Videos
Immature Data Limit Conclusions on Continuous vs Fixed-Duration Frontline CLL Therapies
03/19/2026
Richard Furman, MD
Richard Furman, MD, discusses early results from the CLL-17 trial, underscoring the need for longer follow-up before defining optimal frontline strategies for treatment-naïve patients with chronic lymphocytic leukemia.
Richard Furman, MD, discusses early results from the CLL-17 trial, underscoring the need for longer follow-up before defining optimal frontline strategies for treatment-naïve patients with chronic lymphocytic leukemia.
Richard Furman, MD, discusses...
03/19/2026
Oncology
Matthew Davids, MD
Videos
Genetic Risk Factors May Help Predict Richter Transformation in Chronic Lymphocytic Leukemia
01/05/2026
Matthew S. Davids, MD, MMSc
Matthew Davids, MD, highlights advances in identifying and managing Richter transformation among patients with chronic lymphocytic leukemia.
Matthew Davids, MD, highlights advances in identifying and managing Richter transformation among patients with chronic lymphocytic leukemia.
Matthew Davids, MD, highlights...
01/05/2026
Oncology
Wojciech Jurczak, MD, PhD
Conference Coverage
Frontline Pirtobrutinib Shows Superior PFS vs Bendamustine-Rituximab for CLL/SLL: BRUIN CLL-313 Trial
12/15/2025
Wojciech Jurczak, MD, PhD
According to first results from a phase 3 trial presented by Wojciech Jurczak, MD, PhD, at the 2025 ASH Annual Meeting, pirtobrutinib showed superior PFS and tolerability for treatment-naïve chronic lymphocytic leukemia/small lymphocytic...
According to first results from a phase 3 trial presented by Wojciech Jurczak, MD, PhD, at the 2025 ASH Annual Meeting, pirtobrutinib showed superior PFS and tolerability for treatment-naïve chronic lymphocytic leukemia/small lymphocytic...
According to first results from...
12/15/2025
Oncology
Catherine Coombs, MD
Conference Coverage
Evolving Treatment Strategies for Patients With Chronic Lymphocytic Leukemia
06/28/2025
Catherine Coombs, MD
At the 2025 Great Debates in Hematologic Malignancies meeting , Catherine Coombs, MD, discussed insights into evolving treatment strategies for patients with chronic lymphocytic leukemia.
At the 2025 Great Debates in Hematologic Malignancies meeting , Catherine Coombs, MD, discussed insights into evolving treatment strategies for patients with chronic lymphocytic leukemia.
At the 2025 Great Debates in...
06/28/2025
Oncology
Constantine Tam, MD
Conference Coverage
Zanubrutinib for Patients With del(17p) CLL and SLL: 5-Year Follow-Up From the SEQUOIA Trial
06/03/2025
Constantine S. Tam
Constantine Tam, MD discusses 5-year follow-up results from the SEQUOIA trial evaluating the efficacy of zanubrutinib for patients with chronic lymphocytic leukemia and a chromosome 17p deletion.
Constantine Tam, MD discusses 5-year follow-up results from the SEQUOIA trial evaluating the efficacy of zanubrutinib for patients with chronic lymphocytic leukemia and a chromosome 17p deletion.
Constantine Tam, MD discusses...
06/03/2025
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use